OneMedNet Reports $18.76 Million in Year-to-Date of Contracted Bookings and Publishes “OneMedNet by the Numbers” Growth Recap

OneMedNet posts $18.76M YTD bookings, but revenue conversion remains modest at $1.388M.

What the company is saying

OneMedNet highlights $18.76 million in year-to-date bookings as of November 6, 2026, positioning this as evidence that its commercial strategy is delivering results. The company emphasizes its relationships with industry leaders in pharma and foundational AI, claiming these have streamlined contracting and accelerated bookings. Aaron Green, President & CEO, states that the company's execution has enabled delivery of multi-modal data at the scale required by customers. The announcement is framed as a growth recap, drawing on the company’s November 6, 2026 financial outlook and SEC filings, and is accompanied by an infographic. The company stresses the scale of its iRWD™ platform, which spans over 2,300 sites, 90 million patient journeys, and 270 million studies. The tone is confident, focusing on operational momentum and platform capabilities, but does not address the gap between bookings and recognized revenue. No explanation is given for the slow pace of revenue conversion, and there is no breakdown of customer types or contract values.

What the data suggests

The disclosed figures show $18.76 million in bookings year-to-date, but only $1.388 million has been recognized as revenue through September 30, 2026. This indicates a significant lag between bookings and actual revenue realization, with less than 8% of bookings converted so far. The company’s network scale is large, with over 2,300 sites, 90 million patient journeys, and 270 million studies, suggesting a substantial data asset base. However, the announcement does not provide details on customer composition, contract duration, or the timing of future revenue recognition. There is no information on profitability, cash flow, or margins. The operational metrics are specific, but the lack of financial granularity limits visibility into business quality and growth sustainability. The evidence supports claims of scale and bookings, but not of rapid monetization or customer traction.

Analysis

The announcement presents a positive tone, emphasizing strong bookings ($18.76M YTD) and network scale, but only $1.388M has been converted to revenue through September 30, 2026. There is no disclosure of profitability metrics (net income, EBITDA, margins), so under the Disclosure Completeness Rule, the signal cannot exceed weak_positive. Several claims about the platform's capabilities, regulatory grade, and customer impact are asserted without supporting evidence or third-party validation. The narrative inflates operational scale and strategic effectiveness, but the actual realized financial progress is modest relative to the headline figures. The forward-looking ratio is moderate, with half the key claims projecting future conversion or strategic outcomes. Execution distance is near-term, as revenue conversion is ongoing, but the gap between bookings and recognized revenue highlights execution risk. No large capital outlay is disclosed, so capital intensity is not flagged.

Risk flags

• ●There is a substantial gap between bookings ($18.76 million) and recognized revenue ($1.388 million), raising questions about the timing and certainty of revenue conversion. This lag could indicate long sales cycles, delayed customer onboarding, or risk of non-conversion.
• ●The announcement lacks detail on customer breakdown, contract terms, or the nature of bookings, making it difficult to assess the quality or stickiness of the business. Without this information, investors cannot gauge concentration risk or the likelihood of recurring revenue.
• ●No profitability, margin, or cash flow data is disclosed, leaving investors without insight into the company’s financial health or ability to generate sustainable returns. This omission increases uncertainty around the operational efficiency and cost structure.
• ●The company asserts regulatory decision-grade and AI-ready capabilities for its datasets but provides no third-party validation, certifications, or compliance evidence. This absence raises the risk that platform claims may not translate into competitive advantage or regulatory acceptance.

Bottom line

OneMedNet’s update demonstrates strong headline bookings of $18.76 million year-to-date, but only $1.388 million has been recognized as revenue, highlighting a slow conversion rate and execution risk. The company’s network scale is significant, with over 2,300 sites and hundreds of millions of patient journeys and studies, but the announcement does not clarify how this scale translates into revenue or profitability. The lack of detail on customer composition, contract terms, and financial performance limits the ability to assess business quality and growth durability. Investors should focus on the pace and consistency of future revenue conversion, as well as any disclosure of profitability or customer wins. The most important takeaway is that while operational scale and bookings are growing, the company must demonstrate its ability to turn these into meaningful, recurring revenue.

Announcement summary

(NASDAQ:ONMD) OneMedNet Corporation announced that bookings reached approximately $18.76 million year-to-date as of November 6, 2026. Of this amount, $1.388 million has been converted to revenue through September 30, 2026. The company released a growth recap titled “OneMedNet by the Numbers,” summarizing its commercial and operational trajectory, which is based on its November 6, 2026 financial outlook, prior public disclosures, and SEC filings. Aaron Green, President & CEO of OneMedNet, stated that the company's strategy is working, emphasizing the importance of building strong relationships with industry leaders who hold contracts across pharma and foundational AI. He noted that these relationships have streamlined the contracting process and reduced time to booking. The company’s platform delivers multi-modal data at the scale required by its customers. OneMedNet’s iRWD™ platform provides regulatory decision-grade, AI-ready datasets, including de-identified medical imaging and comprehensive clinical records. The company’s network spans more than 2,300 sites. The network encompasses over 90 million patient journeys and 270 million studies. OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The platform supports applications such as drug development, regulatory submissions, and foundational AI model training.

Disagree with this article?